1. Home
  2. ARQT vs UAA Comparison

ARQT vs UAA Comparison

Compare ARQT & UAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • UAA
  • Stock Information
  • Founded
  • ARQT 2016
  • UAA 1996
  • Country
  • ARQT United States
  • UAA United States
  • Employees
  • ARQT N/A
  • UAA N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • UAA Apparel
  • Sector
  • ARQT Health Care
  • UAA Consumer Discretionary
  • Exchange
  • ARQT Nasdaq
  • UAA Nasdaq
  • Market Cap
  • ARQT 2.1B
  • UAA 2.2B
  • IPO Year
  • ARQT 2020
  • UAA N/A
  • Fundamental
  • Price
  • ARQT $16.93
  • UAA $4.89
  • Analyst Decision
  • ARQT Strong Buy
  • UAA Hold
  • Analyst Count
  • ARQT 7
  • UAA 20
  • Target Price
  • ARQT $19.00
  • UAA $6.91
  • AVG Volume (30 Days)
  • ARQT 1.5M
  • UAA 12.7M
  • Earning Date
  • ARQT 11-05-2025
  • UAA 11-06-2025
  • Dividend Yield
  • ARQT N/A
  • UAA N/A
  • EPS Growth
  • ARQT N/A
  • UAA N/A
  • EPS
  • ARQT N/A
  • UAA 0.23
  • Revenue
  • ARQT $263,464,999.00
  • UAA $5,114,713,000.00
  • Revenue This Year
  • ARQT $72.46
  • UAA N/A
  • Revenue Next Year
  • ARQT $32.00
  • UAA $2.56
  • P/E Ratio
  • ARQT N/A
  • UAA $21.62
  • Revenue Growth
  • ARQT 99.50
  • UAA N/A
  • 52 Week Low
  • ARQT $8.03
  • UAA $4.76
  • 52 Week High
  • ARQT $18.15
  • UAA $11.89
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 57.20
  • UAA 33.48
  • Support Level
  • ARQT $15.13
  • UAA $4.91
  • Resistance Level
  • ARQT $18.15
  • UAA $5.05
  • Average True Range (ATR)
  • ARQT 0.67
  • UAA 0.15
  • MACD
  • ARQT 0.08
  • UAA 0.04
  • Stochastic Oscillator
  • ARQT 60.00
  • UAA 22.73

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.

Share on Social Networks: